Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and above-Reference-Cited by-同舟云学术

Batch-to-batch consistency trial of an adenovirus type-5 vector-based COVID-19 vaccine in adults aged 18 years and above

Published:2022-09-01 Issue:12 Volume:21 Page:1843-1849
ISSN:1476-0584
Container-title:Expert Review of Vaccines
language:en
Short-container-title:Expert Review of Vaccines

Author:

Li Zhuo-Pei¹,Shi Yun-Feng²,Hou Li-Hua³,Jin Peng-Fei²,Ma Shi-Hua⁴,Pan Hong-Xing²,Zhang Jin-Long³,Shan Yong-Mei⁴,Huang Hai-Tao⁵,Wu Shi-Po³,Du Pan⁶⁷,Wang Xue⁵,Wang Li-Li⁴,Wang Rui-Jie⁵,Wang Ying⁵,Wang Xue-Wen⁸,Zhu Feng-Cai¹²⁹^ORCID,Li Jing-Xin¹²⁹

Affiliation:

1. School of Public Health, Nanjing Medical University, Nanjing, P.R. China

2. NHC Key Laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Nanjing, P.R. China

3. Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, P.R. China

4. Guanyun County Center for Disease Control and Prevention, Guanyun, P.R. China

5. CanSino Biologics Inc, Tianjin, P.R. China

6. Vazyme Biotech Co. Ltd, Nanjing, P.R. China

7. Basic Medical Science School, Zhengzhou University, Zhengzhou, P.R. China

8. Shanghai Canming Medical Technology Co Ltd, Shanghai, P.R. China

9. Institute of Global Public Health and Emergency Pharmacy, China Pharmaceutical University, Nanjing, P.R. China

Funder

CanSino Biologics Inc., the National Natural Science Foundation of China under Grant

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,Molecular Medicine,Immunology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14760584.2022.2119133

Reference22 articles.

1. WHO. WHO coronavirus (COVID-19)dashboard [cited 2022 Jun 24]: Available from https://covid19.who.int/

2. WHO. COVID-19 vaccine tracker- vaccines candidates in clinical trials: 2022 viper group COVID 19 vaccine tracker team [cited 2022 Apr 5]: Available from https://covid19.trackvaccines.org/country/ecuador/

3. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

4. National Medical Products Administration. Circular on issuing technical guidelines for clinical comparability of prophylactic vaccines [cited 2022 Jul 4]: Available from https://www.nmpa.gov.cn/yaopin/ypggtg/ypqtgg/20191224104601789.html

5. WHO. Considerations for the assessment of COVID-19 vaccines for listing by WHO [cited 2022 Jun 24]: Available from https://www.who.int/publications/m/item/considerations-for-the-assessment-of-covid-19-vaccines-for-listing-by-who

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Critical Assessment of COVID-19 Genomic Vaccines;Current Topics in Medicinal Chemistry;2023-10

2. Fingerprinting trimeric SARS-CoV-2 RBD by capillary isoelectric focusing with whole-column imaging detection;Analytical Biochemistry;2023-02

3. Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case–control study;Human Vaccines & Immunotherapeutics;2023-01-02